Chronic kidney disease as a catalyst for cerebral microbleeds: understanding the underlying mechanisms and treatment approaches
Open Access
- 25 June 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1578666
Abstract
Cerebral microbleeds (CMBs) are tiny deposits of blood degradation products in the brain that appear as small, low-signal lesions on magnetic resonance imaging paramagnetic susceptibility sequences. They are common forms of the cerebral small-vessel diseases and are thought to be associated with serious consequences such as cognitive decline and increased risk of stroke. Chronic kidney disease (CKD) is a chronic disease in which renal impairment lasts for more than 3 months and is often accompanied by pathophysiologic changes such as inflammation, abnormal vascular endothelial function, and increased oxidative stress. It has been found that chronic renal insufficiency can induce the onset, development, and aggravation of cognitive impairment of CMBs, which may be caused by hypertension, inflammation and immune response, vascular lesions, blood–brain barrier damage, vitamin D deficiency, and so on. Therefore, it is essential to study the mechanism of cerebral microbleeds induced by chronic kidney disease to prevent the occurrence, development, treatment, and prognosis of stroke and related events in patients in the future. This article summarizes the definition, epidemiological investigation, pathophysiological mechanism, correlation, and treatment status of CMBs and CKD.Keywords
This publication has 150 references indexed in Scilit:
- Medial intracranial carotid artery calcifications and hematoma expansion in deep intracerebral hemorrhageAnnals of Clinical and Translational Neurology, 2024
- Oral pyrophosphate protects Abcc6-/- mice against vascular calcification induced by chronic kidney diseaseJournal of Molecular Medicine, 2024
- Preventing spontaneous cerebral microhemorrhages in aging mice: a novel approach targeting cellular senescence with ABT263/navitoclaxGeroScience, 2023
- Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approachesJournal of Molecular Medicine, 2021
- Evaluation of Blood-Brain Barrier Integrity Using Vascular Permeability Markers: Evans Blue, Sodium Fluorescein, Albumin-Alexa Fluor Conjugates, and Horseradish Peroxidase2020
- Advance of antithrombotic treatment in patients with cerebral microbleedJournal of Thrombosis and Thrombolysis, 2020
- Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axisPflügers Archiv - European Journal of Physiology, 2020
- Use of anticoagulant therapy and cerebral microbleeds: a systematic review and meta-analysisJournal of Neurology, 2019
- Cerebral Microbleeds and Thrombolysis: Clinical Consequences and Mechanistic Implications.JAMA Neurology, 2016
- p‐Cresyl sulfate, a uremic toxin, causes vascular endothelial and smooth muscle cell damages by inducing oxidative stressPharmacology Research & Perspectives, 2014